Gingras AC, Raught B, Sonenberg N. Regulation of translation initiation by FRAP/mTOR. Genes Dev. 2001;15(7):807–26.
Raught B, Peiretti F, Gingras AC, et al. Phosphorylation of eucaryotic translation initiation factor 4B Ser422 is modulated by S6 kinases. EMBO J. 2004;23(8):1761–9.
Ruggero D, Pandolfi PP. Does the ribosome translate cancer?. Nat Rev Cancer. 2003;3(3):179–92.
Ruggero D, Sonenberg N. The Akt of translational control. Oncogene. 2005;24(50):7426–34.
Hu H, Juvekar A, Lyssiotis CA, et al. Phosphoinositide 3-Kinase Regulates Glycolysis through Mobilization of Aldolase from the Actin Cytoskeleton. Cell. 2016;164(3):433–46.
Rathmell JC, Fox CJ, Plas DR, et al. Akt-directed glucose metabolism can prevent Bax conformation change and promote growth factor-independent survival. Mol Cell Biol. 2003;23(20):7315–28.
Cantley LC. The phosphoinositide 3-kinase pathway. Science. 2002;296(5573):1655–7.
Jimenez C, Portela RA, Mellado M, et al. Role of the PI3K regulatory subunit in the control of actin organization and cell migration. J Cell Biol. 2000;151(2):249–62.
Jope RS, Roh MS. Glycogen synthase kinase-3 (GSK3) in psychiatric diseases and therapeutic interventions. Curr Drug Targets. 2006;7(11):1421–34.
Cross DA, Alessi DR, Cohen P, et al. Inhibition of glycogen synthase kinase-3 by insulin mediated by protein kinase B. Nature. 1995;378(6559):785–9.
Paraskevopoulou MD, Tsichlis PN. A perspective on AKT 25-plus years after its discovery. Sci Signal. 2017;10:486.
Manning BD, Toker A. AKT/PKB Signaling: Navigating the Network. Cell. 2017;169(3):381–405.
Franke TF, Yang SI, Chan TO, et al. The protein kinase encoded by the Akt proto-oncogene is a target of the PDGF-activated phosphatidylinositol 3-kinase. Cell. 1995;81(5):727–36.
Beaulieu JM. A role for Akt and glycogen synthase kinase-3 as integrators of dopamine and serotonin neurotransmission in mental health. J Psychiatry Neurosci. 2012;37(1):7–16.
Law AJ, Wang Y, Sei Y, et al. Neuregulin 1-ErbB4-PI3K signaling in schizophrenia and phosphoinositide 3-kinase-p110delta inhibition as a potential therapeutic strategy. Proc Natl Acad Sci U S A. 2012;109(30):12165–70.
Goldman-Rakic PS, Castner SA, Svensson TH, et al. Targeting the dopamine D1 receptor in schizophrenia: insights for cognitive dysfunction. Psychopharmacology. 2004;174(1):3–16.
Sotnikova TD, Beaulieu JM, Barak LS, et al. Dopamine-independent locomotor actions of amphetamines in a novel acute mouse model of Parkinson disease. PLoS Biol. 2005;3(8): e271.
Balu DT, Carlson GC, Talbot K, et al. Akt1 deficiency in schizophrenia and impairment of hippocampal plasticity and function. Hippocampus. 2012;22(2):230–40.
Karege F, Perroud N, Burkhardt S, et al. Alteration in kinase activity but not in protein levels of protein kinase B and glycogen synthase kinase-3beta in ventral prefrontal cortex of depressed suicide victims. Biol Psychiatry. 2007;61(2):240–5.
Emamian ES, Hall D, Birnbaum MJ, et al. Convergent evidence for impaired AKT1-GSK3beta signaling in schizophrenia. Nat Genet. 2004;36(2):131–7.
Leibrock C, Ackermann TF, Hierlmeier M, et al. Akt2 deficiency is associated with anxiety and depressive behavior in mice. Cell Physiol Biochem. 2013;32(3):766–77.
Howell KR, Floyd K, Law AJ. PKBgamma/AKT3 loss-of-function causes learning and memory deficits and deregulation of AKT/mTORC2 signaling: Relevance for schizophrenia. PLoS ONE. 2017;12(5): e0175993.
Riviere JB, Mirzaa GM, O’Roak BJ, et al. De novo germline and postzygotic mutations in AKT3, PIK3R2 and PIK3CA cause a spectrum of related megalencephaly syndromes. Nat Genet. 2012;44(8):934–40.
Hobert JA, Embacher R, Mester JL, et al. Biochemical screening and PTEN mutation analysis in individuals with autism spectrum disorders and macrocephaly. Eur J Hum Genet. 2014;22(2):273–6.
Fricker M, Tolkovsky AM, Borutaite V, et al. Neuronal Cell Death. Physiol Rev. 2018;98(2):813–80.
Mishra R, Barthwal MK, Sondarva G, et al. Glycogen synthase kinase-3beta induces neuronal cell death via direct phosphorylation of mixed lineage kinase 3. J Biol Chem. 2007;282(42):30393–405.
Boland E, Clayton-Smith J, Woo VG, et al. Mapping of deletion and translocation breakpoints in 1q44 implicates the serine/threonine kinase AKT3 in postnatal microcephaly and agenesis of the corpus callosum. Am J Hum Genet. 2007;81(2):292–303.
Schizophrenia Working Group of the Psychiatric Genomics. Biological insights from 108 schizophrenia-associated genetic loci. Nature. 2014;511(7510):421–7.
Consortium TSW, Ripke S, Walters JT, et al. Mapping genomic loci prioritises genes and implicates synaptic biology in schizophrenia. medRxiv. 2020:2020.09.12.20192922.
Singh T, Poterba T, Curtis D, et al. Exome sequencing identifies rare coding variants in 10 genes which confer substantial risk for schizophrenia. medRxiv. 2020:2020.09.18.20192815.
Polytarchou C, Hatziapostolou M, Yau TO, et al. Akt3 induces oxidative stress and DNA damage by activating the NADPH oxidase via phosphorylation of p47(phox). Proc Natl Acad Sci U S A. 2020;117(46):28806–15.
Iliopoulos D, Polytarchou C, Hatziapostolou M, et al. MicroRNAs differentially regulated by Akt isoforms control EMT and stem cell renewal in cancer cells. Sci Signal. 2009;2(92):62.
Sanidas I, Polytarchou C, Hatziapostolou M, et al. Phosphoproteomics screen reveals akt isoform-specific signals linking RNA processing to lung cancer. Mol Cell. 2014;53(4):577–90.
Tsimberidou AM, Shaw JV, Juric D, et al. Phase 1 study of M2698, a p70S6K/AKT dual inhibitor, in patients with advanced cancer. J Hematol Oncol. 2021;14(1):127.
Li X, Dai D, Chen B, et al. Efficacy of PI3K/AKT/mTOR pathway inhibitors for the treatment of advanced solid cancers: A literature-based meta-analysis of 46 randomised control trials. PLoS ONE. 2018;13(2): e0192464.
Machl A, Wilker EW, Tian H, et al. M2698 is a potent dual-inhibitor of p70S6K and Akt that affects tumor growth in mouse models of cancer and crosses the blood-brain barrier. Am J Cancer Res. 2016;6(4):806–18.
Baselga J, Im SA, Iwata H, et al. Buparlisib plus fulvestrant versus placebo plus fulvestrant in postmenopausal, hormone receptor-positive, HER2-negative, advanced breast cancer (BELLE-2): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Oncol. 2017;18(7):904–16.
Di Leo A, Johnston S, Lee KS, et al. Buparlisib plus fulvestrant in postmenopausal women with hormone-receptor-positive, HER2-negative, advanced breast cancer progressing on or after mTOR inhibition (BELLE-3): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Oncol. 2018;19(1):87–100.
Shalimova A, Babasieva V, Chubarev VN, et al. Therapy response prediction in major depressive disorder: current and novel genomic markers influencing pharmacokinetics and pharmacodynamics. Pharmacogenomics. 2021;22(8):485–503.
Chadha R, Meador-Woodruff JH. Downregulated AKT-mTOR signaling pathway proteins in dorsolateral prefrontal cortex in Schizophrenia. Neuropsychopharmacology. 2020;45(6):1059–67.
Kitagishi Y, Kobayashi M, Kikuta K, et al. Roles of PI3K/AKT/GSK3/mTOR Pathway in Cell Signaling of Mental Illnesses. Depress Res Treat. 2012;2012: 752563.
Roh MS, Seo MS, Kim Y, et al. Haloperidol and clozapine differentially regulate signals upstream of glycogen synthase kinase 3 in the rat frontal cortex. Exp Mol Med. 2007;39(3):353–60.
Pan B, Huang XF, Deng C. Aripiprazole and Haloperidol Activate GSK3beta-Dependent Signalling Pathway Differentially in Various Brain Regions of Rats. Int J Mol Sci. 2016;17(4):459.
Duda P, Hajka D, Wojcicka O, et al. GSK3beta: A Master Player in Depressive Disorder Pathogenesis and Treatment Responsiveness. Cells. 2020;9:3.
Krishnan V, Han MH, Mazei-Robison M, et al. AKT signaling within the ventral tegmental area regulates cellular and behavioral responses to stressful stimuli. Biol Psychiatry. 2008;64(8):691–700.
Wong H, Levenga J, LaPlante L, et al. Isoform-specific roles for AKT in affective behavior, spatial memory, and extinction related to psychiatric disorders. Elife. 2020;9:897.
Ikeda M, Iwata N, Suzuki T, et al. Association of AKT1 with schizophrenia confirmed in a Japanese population. Biol Psychiatry. 2004;56(9):698–700.
Schwab SG, Hoefgen B, Hanses C, et al. Further evidence for association of variants in the AKT1 gene with schizophrenia in a sample of European sib-pair families. Biol Psychiatry. 2005;58(6):446–50.
Xu MQ, Xing QH, Zheng YL, et al. Association of AKT1 gene polymorphisms with risk of schizophrenia and with response to antipsychotics in the Chinese population. J Clin Psychiatry. 2007;68(9):1358–67.
Magno LA, Miranda DM, Neves FS, et al. Association between AKT1 but not AKTIP genetic variants and increased risk for suicidal behavior in bipolar patients. Genes Brain Behav. 2010;9(4):411–8.
Pereira PA, Bicalho MA, de Moraes EN, et al. Genetic variant of AKT1 and AKTIP associated with late-onset depression in a Brazilian population. Int J Geriatr Psychiatry. 2014;29(4):399–405.
Losenkov IS, Vyalova NM, Simutkin GG, et al. An association of AKT1 gene polymorphism with antidepressant treatment response. World J Biol Psychiatry. 2016;17(3):239–42.
Bergeron Y, Bureau G, Laurier-Laurin ME, et al. Genetic Deletion of Akt3 Induces an Endophenotype Reminiscent of Psychiatric Manifestations in Mice. Front Mol Neurosci. 2017;10:102.
Chia S, Gandhi S, Joy AA, et al. Novel agents and associated toxicities of inhibitors of the pi3k/Akt/mtor pathway for the treatment of breast cancer. Curr Oncol. 2015;22(1):33–48.
Ezell SA, Polytarchou C, Hatziapostolou M, et al. The protein kinase Akt1 regulates the interferon response through phosphorylation of the transcriptional repressor EMSY. Proc Natl Acad Sci U S A. 2012;109(10):E613–21.
Thomas CC, Deak M, Alessi DR, et al. High-resolution structure of the pleckstrin homology domain of protein kinase b/akt bound to phosphatidylinositol (3,4,5)-trisphosphate. Curr Biol. 2002;12(14):1256–62.
Lee MS, Feig M, Salsbury FR Jr, et al. New analytic approximation to the standard molecular volume definition and its application to generalized Born calculations. J Comput Chem. 2003;24(11):1348–56.
Feig M, Onufriev A, Lee MS, et al. Performance comparison of generalized born and Poisson methods in the calculation of electrostatic solvation energies for protein structures. J Comput Chem. 2004;25(2):265–84.